TG Therapeutics Stock News

Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday. H

Companies in The News Are: IMGN, TGTX, TSLA, MSFT

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. Shaw Communications Inc. (NYSE: SJR) shares jumped 10.3% to $29.11 in p

Wednesday, the FDA approved TG Therapeutics Inc's (NASDAQ: TGTX) Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). Briumvi is the first and only anti-CD20 monoclonal antibo

Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. Quotient Limited (NASDAQ: QTNT) shares jumped 124% to $0.5382 afte

HC Wainwright & Co. has decided to maintain its Buy rating of TG Therapeutics (NASDAQ:TGTX) and raise its price target from $19.00 to $24.00. Shares of TG Therapeutics are trading up 24.47% over the l

B of A Securities has decided to maintain its Underperform rating of TG Therapeutics (NASDAQ:TGTX) and raise its price target from $5.00 to $6.00. Shares of TG Therapeutics are trading up 24.47% over

The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023. Stock up.

Morgan Stanley cut Tesla, Inc. (NASDAQ: TSLA) price target from $330 to $250. Morgan Stanley analyst Adam Jonas maintained an Overweight rating on the stock. Tesla shares rose 4.4% to $117.65 in p

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. Hyzon Motors Inc. (NASDAQ: HYZN) shares climbed 12.9% to $1.58 in pre

The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023.

Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nas

TG Therapeutics Inc TGTX shares are trading higher by 9.34% to $9.25 Thursday morning. The company on Wednesday revealed FDA approval of ublituximab.

The stock market lost ground as economic worries persist.

BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the